Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures usually occur early after infusion. The purpose of our study was to identify factors that may predict failure, particularly early...

Celý popis

Podrobná bibliografie

Vydáno v:	Blood advances Ročník 4; číslo 22; s. 5607 - 5615
Hlavní autoři:	Vercellino, Laetitia, Di Blasi, Roberta, Kanoun, Salim, Tessoulin, Benoit, Rossi, Cedric, D'Aveni-Piney, Maud, Obéric, Lucie, Bodet-Milin, Caroline, Bories, Pierre, Olivier, Pierre, Lafon, Ingrid, Berriolo-Riedinger, Alina, Galli, Eugenio, Bernard, Sophie, Rubio, Marie-Thérèse, Bossard, Celine, Meignin, Veronique, Merlet, Pascal, Feugier, Pierre, Le Gouill, Steven, Ysebaert, Loic, Casasnovas, Olivier, Meignan, Michel, Chevret, Sylvie, Thieblemont, Catherine
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Inc 24.11.2020 The American Society of Hematology American Society of Hematology
Témata:	Cancer Hematology Human health and pathology Humans Immunotherapy, Adoptive Life Sciences Lymphoid Neoplasia Lymphoma, Large B-Cell, Diffuse - diagnosis Lymphoma, Large B-Cell, Diffuse - therapy Progression-Free Survival Retrospective Studies Tumor Burden
ISSN:	2473-9529, 2473-9537, 2473-9537
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!